Table 2.

Differences in the baseline clinicopathological features between the reclassification and non-reclassification groups

	Reclassification group (n = 25)	Non-reclassification group (n = 42)	p value
Age
Median (range)	69 (60–78)	70 (55–79)	0.682*
Mean ± SD	69.48 ± 4.80	69.57 ± 4.96
Prostate volume (cc)
Median (range)	31.3 (8–102.8)	40.3 (15–97.8)	0.049*
Mean ± SD	41.08 ± 19.34	43.99 ± 18.89
Total PSA (ng/ml)
Median (range)	6.4 (3.9–17.0)	6.05 (2.9–13.0)	0.831*
Mean ± SD	7.31 ± 3.58	6.92 ± 2.80
PSAD (ng/ml/cc)
Median (range)	0.18 (0.9–0.84)	0.15 (0.06–0.50)	0.089*
Mean ± SD	0.25 ± 0.20	0.18 ± 0.11
Gleason score
5 (%)	3 (12.0 %)	5 (11.9 %)	1.000**
6 (%)	22 (88.0 %)	37 (88.1 %)
No. of positive cores
1 (%)	16 (64.0 %)	35 (83.3 %)	0.073**
2 (%)	9 (34.0 %)	7 (16.7 %)
No. of biopsy core taken
6–8 (%)	19 (76.0 %)	22 (52.4 %)	0.047**
9–12 (%)	6 (24.0 %)	20 (47.6 %)
% of positive cores
Median (range)	16.7 (8.3–33.3)	12.5 (8.3–33.3)	0.023*
Mean ± SD	17.70 ± 7.65	14.09 ± 6.66
10.0 or less (%)	4 (16.0 %)	16 (38.1 %)	0.048**
Greater than 10.0 (%)	21 (84.0 %)	26 (61.9 %)
% of maximum cancer involvement (%)
Median (range)	10 (3.6–30)	11.75 (2.1–42.9)	0.943*
Mean ± SD	14.02 ± 9.11	13.67 ± 8.88

% of maximum cancer involvement; occupancy of maximum cancer length (mm)/total core length (mm) in positive biopsy specimen × 100 (%)

* Mann-Whitney U test, ** Chi-square test